The antitumorigenic effects of HO-1 have also been demonstrated in human and rat breast cancer, where its overexpression correlates with inhibition of cell proliferation [225] and in pancreatic and prostate cancer, where it is associated with a decrease in cell proliferation and invasiveness by a down regulation of the proangiogenic mediators VEGF and MMP-9 [97,195,226]. This evidence concerns the gene HMOX1 and prostate carcinoma.